Moxifloxacin HCl

Catalog No.S1465

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.

Price Stock Quantity  
In DMSO USD 160 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Moxifloxacin HCl Chemical Structure

Moxifloxacin HCl Chemical Structure
Molecular Weight: 437.89

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Moxifloxacin HCl is available in the following compound libraries:

Product Information

  • Compare Topoisomerase Inhibitors
    Compare Topoisomerase Inhibitors
  • Research Area

Product Description

Biological Activity

Description Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.
Targets
IC50
In vitro Moxifloxacin exerts its effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. Moxifloxacin shows in-vitro potency against M. tuberculosis H37Rv with MIC of 0.177 μg/mL. Moxifloxacin has broad Grampositive and Gram-negative activity. Moxifloxacin shows in vitro and clinical efficacy against Staphylococcus aureus, Streptococcus pneumoniae, Str. pyogenes, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae and Mycoplasma pneumoniae. Moxifloxacin has activity against mycobacteria in addition to M. tuberculosis; Moxifloxacin is more active against M. kansasii than M. avium complex: specifically MIC90 for M. avium > M. intracellulare > M. kansasii at 4, 2 and 2 μg/mL, respectively. MIC90 for M. chelonae > M. fortuitum at 16 and 0.5 μg/mL, respectively. [1]
In vivo Moxifloxacin combined with RIF/pyrazinamide (PZA) reduces treatment time by up to 2 months compared to regimens with isoniazid (INH)/RIF/PZA in a mouse model designed to mimic human disease. Similar results with a stable cure are reached after 4 months in mice treated twice weekly with RIF/Moxifloxacin/PZA compared to cure in 6 months when daily treated with RIF/INH/PZA. 100 mg/kg Moxifloxacin in mice gives activity comparable to INH; increased dose in mice to 400 mg/kg Moxifloxacin daily results in spleen CFU counts lower than for INH 25 mg/kg although the differences are not statistically significant. AUC/MIC ratio correlates best with in-vivo efficacy for the fluoroquinolones in a mouse model of tuberculosis. [1]
Features

Protocol(Only for Reference)

1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01936480 Not yet recruiting Cardiac Arrhythmias Massachusetts General Hospital 2013-10 Phase 4
NCT01968733 Recruiting Community-acquired Bacterial Pneumonia Cempra Pharmaceuticals 2013-11 Phase 3
NCT01803399 Not yet recruiting Infections, Bacterial GlaxoSmithKline 2014-03 Phase 1
NCT01984827 Not yet recruiting Diabetes Richmond Pharmacology Limited 2014-03 Phase 1
NCT01515826 Not yet recruiting Cataracts Alcon Research 2014-03 Phase 3

Chemical Information

Download Moxifloxacin HCl SDF
Molecular Weight (MW) 437.89
Formula

C21H24FN3O4.HCl

CAS No. 186826-86-8
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms Avelox, Avalox
Solubility (25°C) * In vitro DMSO 88 mg/mL (200 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.43789 4.3789 8.7578 13.1367

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Topoisomerase Inhibitors

  • SN-38

    SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.

  • Beta-Lapachone

    Beta-Lapachone is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. Phase 2.

  • BMN 673

    BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 1.

    Features:Most potent and selective PARPi reported thus far.

  • Doxorubicin (Adriamycin)

    Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

  • Etoposide

    Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

  • Camptothecin

    Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM. Phase 2.

  • Topotecan HCl

    Topotecan (NSC 609699) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM, respectively.

    Features:Topotecan is a water-soluble derivative of camptothecin.

  • Irinotecan

    Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

    Features:Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.

  • Idarubicin HCl

    Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL.

    Features:Idarubicin is a substrate for CYP450 2D6 and 2C9.

  • Epirubicin HCl

    Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase.

Recently Viewed Items

Tags: buy Moxifloxacin HCl | Moxifloxacin HCl ic50 | Moxifloxacin HCl price | Moxifloxacin HCl cost | Moxifloxacin HCl solubility dmso | Moxifloxacin HCl purchase | Moxifloxacin HCl manufacturer | Moxifloxacin HCl research buy | Moxifloxacin HCl order | Moxifloxacin HCl mouse | Moxifloxacin HCl chemical structure | Moxifloxacin HCl mw | Moxifloxacin HCl molecular weight | Moxifloxacin HCl datasheet | Moxifloxacin HCl supplier | Moxifloxacin HCl in vitro | Moxifloxacin HCl cell line | Moxifloxacin HCl concentration | Moxifloxacin HCl nmr
Contact Us